20.06.2013
- Forest Laboratories, the specialty drugmaker that counts investor Carl Icahn as a major shareholder, is among a handful of companies interested in bidding for Irish drugmaker Elan...
19.06.2013
- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week...
13.06.2013
- When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the...
07.06.2013
- Royalty Pharma received a blow in its battle to take over Irish drug firm Elan on Thursday after a ruling on conditions attached to the U.S. company's hostile bid threatened to...
13.05.2013
- Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21% of the royalties that U.S. company Theravance receives from GlaxoSmithKline for...
22.04.2013
- The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S. investment firm's offer of $11.25 a share grossly undervalues the...
19.04.2013
- U.S. healthcare firm Johnson & Johnson cut its stake in Elan on Thursday in a move that clouds prospects for a $7.3 billion takeover bid for the Irish drugmaker. U.S. investment...
12.04.2013
- U.S. investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug...
